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Theodore H. Yuo, MD, Philip P. Goodney, MD, Richard J. Powell, MD, and Jack L. Cronenwett, MD,
Lebanon, NH
Background: While medical high risk (MHR) has been proposed as an indication for carotid artery stenting (CAS), the
impact of MHR on long-term survival and stroke after CAS has not been described.
Methods: A retrospective chart review of CAS procedures at our institution was performed. One hundred seventy-nine
consecutive patients who underwent 196 CAS procedures were classified by MHR status based on cardiac, pulmonary,
and renal criteria routinely used in high-risk clinical trials. Survival and stroke rates were compared after 90 CAS
procedures in MHR patients vs 106 CAS procedures in normal risk patients. Survival results were also compared with 365
contemporaneous carotid endarterectomy (CEA) procedures in 346 patients.
Results: The mean age of CAS patients was 72 years, with 87% having a smoking history, 85% hypertension, 38% diabetes,
39% symptomatic, and 74% documented coronary artery disease. Mean follow-up was 23 months. Recurrent stenosis after
CEA comprised 21% of all CAS procedures. During the 30-day post-procedure period, there were five minor strokes, one
major stroke, and one death, for a combined stroke/death rate of 3.6%. Kaplan-Meier analysis demonstrated mortality of
5% at 1 year and 21% at 3 years for the entire cohort. Cox regression analysis found that MHR designation was not
associated with increased mortality or an increase in a composite end point of death or stroke. MHR patients had
mortality of 4% at 1 year and 22% at 3 years. Normal risk patients had mortality of 6% at 1 year and 20% at 3 years.
Preoperative age over 80 years old, low density lipoprotein (LDL) >160 mg/dL, and serum creatinine >1.5 mg/dL
conferred statistically significant risk for death (Hazard ratios: 2.9, 4.3, and 2.4, respectively). As a point of comparison,
a contemporaneous group of CEA patients were analyzed similarly. After adjusting for age over 80 years old and serum
creatinine >1.5 mg/dL, there was no survival difference between MHR patients undergoing CAS or CEA.
Conclusions: The presence of MHR did not impact long-term survival or stroke rate after CAS, and overall survival of
MHR patients in our series was comparable with risk-adjusted controls undergoing CEA. These results suggest the need
for more refined predictors of medical risk to optimally guide patients in selecting carotid revascularization strategies.
( J Vasc Surg 2008;47:356-62.)Carotid artery atherosclerotic disease is a major cause of
ischemic stroke, being an underlying cause in 10% to 20% of
patients presenting with stroke.1 Randomized controlled
trials have demonstrated durable benefit from carotid end-
arterectomy (CEA) in symptomatic and asymptomatic pa-
tients that have been appropriately selected.2,3,4,5,6,7 In
fact, many have deemed CEA to be the “gold standard” in
carotid revascularization.8
However, some patients with severe coronary, pulmo-
nary, and renal disease are considered to be at medical high
risk (MHR) for CEA, and they have been shown to have
higher rates of stroke, myocardial infarction, and death
after CEA than patients without such risk factors.9 For
these patients, many consider carotid artery stenting (CAS)
to be an alternative, and perhaps equivalent, treatment
option. Although controversial, the Stenting and Angio-
plasty with Protection in Patients at High Risk for Endar-
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356terectomy trial (SAPPHIRE) concluded that CAS was not
inferior to CEA among patients who were at medical or
surgical high risk for carotid endarterectomy.10 However,
the same medical comorbidities that made these patients
eligible for CAS raise the concern that these patients might
have increased late mortality and might not live long
enough to benefit from carotid revascularization. This is
especially true when treating asymptomatic patients, who
comprise the majority of patients enrolled into many ran-
domized trials and registries.11
Therefore, we reviewed the records at our institution of
patients who underwent CAS, and examined the effect of
MHR designation on midterm survival. To provide a com-
parison with endarterectomy, we also compared survival
after CAS with a contemporaneous group of patients un-
dergoing CEA at our institution.
METHODS
Study design and patient selection. A retrospective
review was conducted of all patients who underwent CAS
for extracranial carotid bifurcation disease from December
2000 through August 2006. This study was approved by
the Institutional Review Board at Dartmouth-Hitchcock
Medical Center (DHMC), Lebanon, NH. We included
only patients undergoing CAS for bifurcation disease. We
excluded those patients who underwent isolated proximal
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other indications such as dissection, trauma, or aneurysm.
Medical high risk determination. We reviewed the
recent literature and current clinical trials in order to iden-
tify MHR criteria used in major high-risk CAS stud-
ies,10,12,13 and then used these to define inclusion criteria
to designate patients as MHR for this study. These criteria
are identified in Table I. Based on medical records available
before the procedure, patients were then classified as being
at MHR for conventional CEA if they fulfilled any of the
cardiac, pulmonary, or renal criteria listed.
Two authors (THY and PPG) independently reviewed
patient records and assigned MHR designation according
to these criteria. Any designations that were ambiguous or
uncertain were arbitrated by a third author (RJP). If these
patients did not fulfill any of these criteria, they were
deemed to be at normal risk (NR). Anatomic risk factors for
CEA, such as previous ipsilateral CEA or a history of
cervical radiation therapy, were not considered in this anal-
ysis.
CAS procedures. CAS procedures were performed as
previously described.14 Patients generally received clopi-
dogrel, 75 mg/d for 1 week, or a single 300-mg loading
dose of clopidogrel orally on the morning of the procedure.
In addition, patients were given oral aspirin throughout the
periprocedure period. Carotid artery access was obtained
via either a femoral or carotid approach, and in most cases,
an embolic protection device (EPD) was then deployed
before a carotid artery stent was placed. Patients remained
in the recovery room for 4 to 6 hours. If no hemodynamic
instability occurred, they were transferred to a standard
hospital room. The morning after the procedure, a carotid
duplex scan was obtained, and patients were subsequently
discharged on aspirin and clopidogrel 75 mg/d for 1
month. Carotid duplex scanning was performed at 24
hours, 1 and 6 months, and yearly thereafter.
Embolic protection devices (EPDs) used included the
GuardWire in 51% (PercuSurge/Medtronic Vascular,
Table I. Inclusion criteria for medical high risk for
carotid endarterectomy
High-risk category Criteria
Cardiac dysfunction NYHA class III or IV CHF
LVEF 30%
CCS class III or IV angina
Positive cardiac stress test
Pulmonary dysfunction Chronic oxygen therapy
pO2 60 mm Hg
FEV1 50% predicted
DLCO 50% of predicted
Renal dysfunction Serum creatinine 3 mg/dL
Dialysis dependence
NYHA, New York Heart Association; CHF, congestive heart failure pO2,
partial pressure of oxygen in arterial blood; LVEF, left ventricular ejection
fraction; CCS, Canadian Cardiovascular Society; FEV1, forced expiratory
volume in 1 second; DLCO, diffusing capacity of the lungs for carbon
monoxide.Santa Rosa, Calif), the Accunet in 22% (Guidant, St. Paul,Minn), the Emboshield in 20% (Abbott Laboratories, Ab-
bott Park, Ill), the AngioGuard in 5% (Cordis, Miami
Lakes, Fla), and the FilterWire in 1% (Boston Scientific,
Natick, Mass). Reversal of flow was used in one case, and no
protection method was used in two cases.
Stents used included the Wallstent in 53% (Boston
Scientific, Natick, Mass), the Acculink in 21% (Guidant, St.
Paul, Minn), the Xact in 15% (Abbott Laboratories, Abbott
Park, Ill), the Precise in 7% (Cordis, Miami Lakes, Fla), and
the ViVEXX in 4% (Bard Peripheral Vascular, Tempe,
Ariz). In one case, a Cypher sirolimus-eluting coronary
stent (Cordis, Miami Lakes, Fla) was used for a patient with
recurrent intimal hyperplasia. Similarly, an ICast covered
stent (Atrium Medical, Hudson, NH) was used in another
patient with recurrent intimal hyperplasia.
CEA procedures. We then sought to examine survival
across risk strata, between patients undergoing CAS and
CEA. Therefore, a contemporary group of patients who
had undergone CEA at DHMC between August 2002 and
August 2006 was utilized to provide a reference point. We
studied 365 CEAs in 346 patients. Chart and database
review allowed determination of pre-existing medical co-
morbidities, such that the patients were then classified as
MHR or NR for CEA in a fashion similar to the CAS
cohort. A total of 38 (10%) of the CEA procedures oc-
curred in patients who were MHR. Survival status was
ascertained in a fashion similar to the CAS patients.
Outcomes definitions. Patients underwent a neuro-
logic examination performed by a general surgery chief
resident or vascular fellow in addition to the surgical at-
tending physician on post-procedure day 1 and at each
clinic visit thereafter. Patients were not consistently exam-
ined by an independent neurologist, though later in our
series almost all patients underwent independent neurolo-
gist evaluation. Any new neurologic deficits were scored
with the National Institutes of Health (NIH) Stroke Scale.
A major stroke was defined as a new neurologic event that
lasted longer than 24 hours, with an increase in the NIH
Stroke Scale greater than or equal to 3. A minor stroke was
defined as a new neurologic event that lasted longer than 24
hours and was associated with an increase in the NIH
Stroke Scale of less than 3. A transient ischemic attack
(TIA) was defined as a new neurologic deficit that lasted
less than 24 hours. A neurologic deficit that developed
during deployment of the EPD that completely resolved with
its removal was not considered a TIA, but as failure of embo-
lization protection.
Follow-up procedures and analysis. Subsequent sur-
vival and stroke were ascertained through the use of avail-
able medical records, and if recent medical records were not
available, the patient, patient’s family, or the patient’s pri-
mary care provider was directly contacted by telephone to
determine survival status and establish a follow-up visit in
clinic. If the patient could not be contacted, the patient’s
family or primary care provider was contacted to determine
the patient’s survival status. Stroke status was not deter-
mined through the telephone interview.
schem
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where noted. Demographic data were analyzed with the
use of Student t tests or Pearson 2 tests, as appropriate.
Rates of survival and stroke were estimated using the
Kaplan-Meier method for patients undergoing CAS. Dif-
ferences in survival between various groups of patients were
estimated with the use of the Cox proportional hazards
regression. Analysis was performed with STATA 9.0 (Stata
Corp, College Station, Texas) and Microsoft Office Excel
2003 (Microsoft Corporation, Redmond, Wash).
RESULTS
Patient demographics and results of CAS.
Demographic and clinical data for the patients undergoing
CAS are presented in Table II. A total of 196 CAS proce-
dures were performed in 179 patients, with 46% of the
procedures being done in MHR patients. Mean CAS
follow-up was 23 1 months. Mean patient age was similar
at the time of the procedure between NR and MHR
patients (71 vs 73 years old), as was the prevalence of male
patients (79% vs 78%). Clinical presentation was also simi-
lar, with 66% and 56% of the patients being asymptomatic,
respectively. In terms of cardiovascular risk factors, 57% of
the NR group and 94% of the MHR group (P  .001) had
a documented history of coronary artery disease. The pres-
ence of other risk factors, including diabetes mellitus, hy-
pertension, dyslipidemia, and a history of smoking, was
comparable between the two groups. Preoperative creati-
nine was significantly higher in the MHR group (1.1 g/dL
vs 1.4 g/dL, P  .004). NR patients had a significantly
higher chance of having anatomic factors that would confer
Table II. Demographic data and frequency of clinical vari
Demographic data
CAS: medical n
risk (n  10
Number of patients 96
Mean age (y) 71.0  0.
Male gender 79%
Symptom status









Preoperative creatinine (mg/dL) 1.13  0.
Preoperative LDL (mg/dL) 97  4
Vascular history
History of any previous vascular surgery 50%
History of previous ipsilateral CEA 29%
Presence of anatomic high risk factors 60%
Radiographic ICA stenosis 81%
Contralateral ICA stenosis or occlusion 22%
CAS, Carotid artery stenting; CEA, carotid endarterectomy; TIA, transient i
significant.additional risk for CEA compared with MHR patients (60%vs 38%; P  .002). Mean radiographic ICA stenosis was
similar in both NR and MHR patients (81% vs 82%), as was
the presence of a contralateral ICA occlusion (22% vs 20%).
Among patients with MHR factors, cardiac comorbid-
ity was the most common criterion for MHR status fol-
lowed by pulmonary, and then renal comorbidities (Table
III). Most patients were MHR in only one category, while
six of the procedures were done in patients who had both
cardiac and pulmonary comorbidities, and one procedure
was done in a patient who had a cardiac and a renal
comorbidity.
Outcomes of CAS. During the immediate periproce-
dural period, there were three minor strokes and two major
strokes. During the 30-day post-procedural period, there
in patients undergoing CAS
l CAS: medical high
risk (n  90)
CAS: all
(n  196) P value
83 179










1.39  0.08 1.3  0.05 .004






ic attack; LDL, low density lipoprotein; ICA, internal carotid artery; NS, not











Previous CEA 41 21
Distal extent 19 10
Othera 4 2
None 42 21
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
Several patients fulfilled criteria for multiple high risk categories.





04was one minor stroke and one death, for a combined
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of 28 patients had died, after undergoing 30 CAS proce-
dures. One additional minor stroke was detected during the
follow-up period.
Kaplan-Meier analysis for all patients demonstrated
mortality of 5% at 1 year and 21% at 3 years. NR mortality
was 6% at 1 year and 20% at 3 years, which was similar to the
mortality for MHR patients that were 4% at 1 year and 22%
at 3 years (Fig 1). Analysis of death rates using Kaplan-
Meier and Cox proportional hazards analysis showed no
difference in rate of death between MHR patients and NR
patients (Hazard ratio [HR]  0.89, 95% CI: 0.43-1.82).
Kaplan-Meier analysis for the composite end point of stroke
or death revealed similar findings. For all patients, the rate
of stroke or death at 1 year and 3 years was 7% and 24%,
respectively. NR stroke or death rates were 7% at 1 year and
23% at 3 years, while the corresponding rate for MHR
patients was 7% at 1 year and 25% at 3 years. This composite
end point of stroke or death was not increased among
MHR patients compared with NR patients (HR  0.91,
95% CI: 0.47-1.75).
Univariate Cox proportional hazards analysis of avail-
able preoperative variables revealed three significant risk
factors for reduced survival. These were: age80 years old,
serum LDL 160 mg/dL, and serum creatinine 1.5
mg/dL. Of note, MHR designation did not predict worse
survival (HR 0.89, 95% CI 0.43-1.82). Many other vari-
ables were analyzed; however, none other than the three
listed above had any significant ability to predict death
following CAS (Table IV).
We then examined if age over 80, which has been
shown in several prior studies to predict poor outcomes
after CAS, also predicts poor survival after CAS. Kaplan-
Meier estimate of the survival function comparing patients
older than 80 years old with patients younger than 80 years
old at the time of CAS demonstrates a higher risk of death (Fig
2) among the patients over age 80. One and 3 year mortality
was 4% and 15% among patients younger than 80 years old,
compared with 7% and 45% among octogenarians.
Comparison with CEA. Demographic data for CEA
Fig 1. Kaplan-Meier survival estimates comparing medical high
risk and medical low risk patients.patients is compared with CAS patients in Table V. Asexpected, CAS patients were significantly older (70 years vs
72 years), were significantly more likely to be male (62% vs
79%) and had a significantly higher creatinine level (1.1
mg/dL vs 1.3 mg/dL). A similar percentage of both
groups had asymptomatic lesions (57% vs 61%). As ex-
pected, CEA patients were significantly less likely to have an
identified medical high risk factor (10% vs 46%). Mean CEA
follow-up was 22  1 months.
Univariate Cox proportional hazards analysis revealed
Table IV. Hazard ratios of potential predictive factors








Medical high risk* 0.89 0.43-1.82 NS
Age 80 y old 2.86 1.34-6.10 .007
Preoperative LDL 160
mg/dL 4.30 1.23-15.0 .022
Preoperative creatinine 1.5
mg/dL 2.37 1.15-4.86 .019
Diabetes mellitus 1.23 0.60-2.54 NS
Hypertension 1.47 0.51-4.23 NS
Dyslipidemia 0.43 0.16-1.14 NS
Male gender 1.09 0.42-2.84 NS
Presence of a symptomatic
lesion 1.13 0.55-2.32 NS
History of CAD 0.73 0.32-1.66 NS
History of ipsilateral CEA 0.25 0.06-1.06 NS
Cardiac risk factor* 0.81 0.38-1.70 NS
Pulmonary risk factor* 1.02 0.31-3.38 NS
Renal risk factor* 1.68 0.23-12.4 NS
Coumadin usage 1.64 0.67-4.03 NS
Past or present tobacco usage 0.42 0.17-1.03 NS
LVEF 30% 1.04 0.23-4.67 NS
Statin usage 0.59 0.27-1.30 NS
Beta blocker usage 0.83 0.40-1.72 NS
ACE/ARB usage 0.60 0.29-1.23 NS
ACE, Ace inhibitor; ARB, angiotensin receptor blocker; CAD, coronary
artery disease; CAS, Carotid artery stenting; CEA, carotid endarterectomy;
LVEF, left ventricular ejection fraction; NS, not significant.
*Cardiac, pulmonary, and renal risk factors for high risk for CEA are defined
in Table I.
Fig 2. Kaplan-Meier estimates of survival comparing octogenari-
ans with non-octogenarians.that CAS patients died at a significantly higher rate than
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3-year postoperative survival for CEA patients was 96% and
91%, while CAS survival was 95% and 79%, respectively.
Additionally, preoperative age 80 years old (HR 3.02,
95% CI 1.73-5.25) and preoperative serum creatinine
1.5 mg/dL (HR 2.63, 95% CI 1.52-4.55) were associ-
ated with an increased risk of death. MHR factors were not
found to be significant for death. However, after adjusting
for age and preoperative serum creatinine, Cox propor-
tional hazards analysis does not reveal CAS to be signifi-
cantly associated with death compared with CEA in MHR
patients (HR 1.45, 95% CI 0.49-4.49). Survival analysis of
MHR CEA patients and CAS patients is shown in Fig 3.
Nearly 90% of patients were alive at 1 year, and nearly 80%
were alive at 3 years. Despite designation as MHR and
undergoing surgical intervention, there was no significant
difference in survival between CAS and high or low risk CEA
patients, even at 4 years follow-up by life table analysis.
DISCUSSION
Our work demonstrates that, in midterm follow up, the
presence of MHR did not impact survival or stroke rate
after CAS, and overall survival of MHR patients in our
series was comparable with controls undergoing CEA.
Many perceive CAS as an alternative to CEA for patients
who would be poor surgical candidates, especially those
designated as medical high risk.15 However, while MHR
designation may affect periprocedural complication rates in
CAS, MHR designation does not appear to be associated
with decreased long-term survival following CAS. Given
that patients designated as “medically high risk” live just as
long as the “normal risk” patients, we find it questionable
that any real distinction exists between these groups based
on current “medical high risk” criteria. Our data highlights
the need for more refined predictors of medical risk to
optimally guide patients in selecting carotid revasculariza-
tion strategies.
Few would argue the role of CAS in the treatment of
Table V. Comparison of CAS and CEA patient
populations
Demographic data CEA CAS
P
value
Number of procedures 365 196 —
Number of patients 346 179 —
Mean age (y)  SEM 69.6  0.5 71.7  0.7 .01
Male gender 62% 79% .001
Preoperative creatinine
(mg/dL)  SEM 1.1  0.02 1.3  0.05 .001
Follow-up (mo) 22.3  0.8 23.4 NS
Asymptomatic 57% 61% NS
High cardiac risk 9% 38% .001
High pulmonary risk 1% 10% .001
High renal risk 0% 2% NS
At least one MHR factor 10% 46% .001
CAS, Carotid artery stenting; CEA, carotid endarterectomy; MHR, medical
high risk.extracranial carotid occlusive disease has been clearly de-fined. Randomized controlled trials comparing CEA with
CAS that have been reported include SAPPHIRE, which
demonstrated that CAS was not inferior to CEA;15 the
Endarterectomy vs Angioplasty in Patients with Symptom-
atic Severe Carotid Stenosis (EVA-3S) trial, which demon-
strated superior outcomes with CEA;16 and the Stent-
Supported Percutaneous Angioplasty of the Carotid Artery
vs Endarterectomy (SPACE) trial, which failed to show the
noninferiority of CAS compared with CEA in the 30-day
perioperative period.17 Our study refutes the argument
that patients with large comorbidity burdens are better
served by endovascular therapy than surgery; as we demon-
strated no distinct survival advantage. Further, the long-
term durability of CAS has yet to be demonstrated. To our
knowledge, this present study of CAS patients has the
longest follow-up yet described in the North American or
European vascular surgery literature. We believe that our
finding that MHR patients do not suffer from increased
long-term mortality or stroke compared with NR patients
after CAS is important, especially when combined with our
finding that MHR patients are not at higher risk of mortal-
ity after CAS compared with CEA patients. These results
suggest that MHR is not a good discriminator of outcomes,
though a larger, prospective study of long-term outcomes
would be needed to verify this possibility.
The fact that MHR patients had similar outcomes as
NR patients after CEA was surprising to us, and we have
generated two hypotheses as to why this could be true.
First, patients categorized as MHR in our database have, by
definition, been identified by their health care providers as
having cardiac, pulmonary, or renal disease. The fact that
they were identified as MHR could be affecting the inten-
sity of the medical treatment that they are receiving for
these comorbid conditions, which could be present, but
under treated in the NR group. Guidelines from the Na-
tional Cholesterol Education Project (NCEP) suggest that
patients with significant carotid artery disease have a coronary
heart disease equivalent and should be aggressively treated
Fig 3. Kaplan-Meier estimates of survival comparing MHR CEA
and CAS patients, adjusted for age 80 and preoperative serum
creatinine.with cholesterol lowering medications to achieve a low density
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database was not designed to collect data around longitu-
dinal adherence to medication or long-term control of risk
factors, but the fact that patients with preoperative LDL
levels over 160 mg/dL are at a statistically significantly
higher risk of death than patients with better preoperative
control suggests that lipid control is an important part of
the postoperative care that these patients should receive.
Second, these MHR factors were originally devised as a way
to identify patients that are at high risk for complications
after CEA, not to determine long-term survival. As such, it
may be unsurprising that, given appropriate medical care,
classification as MHR has no bearing on long-term survival.
Our finding that age over 80 years old is a significant
risk factor for CAS supports other findings in the literature
that suggest that octogenarians are at heightened risk of
death and other complications after CAS.19,20,21 Our ex-
perience suggests that octogenarians may only expect to
live about 3 years after CAS on average. As a result, it seems
unlikely that asymptomatic patients over 80 years old
would significantly benefit from prophylactic CAS given
their shorter life expectancy. On the other hand, a broader
question raised by our findings is whether or not MHR
patients less than 80 years of age should be offered CAS,
given similar long-term survival in MHR patients compared
with CEA. We believe, based on the survival data demon-
strated in our cohort that asymptomatic patients80 years
of age may gain benefit from prophylactic CAS in properly
selected cases. Further studies need to be performed to
determine the risk-benefit ratio of CAS, most importantly
in the asymptomatic patient population.
Our study has several limitations. First, not all patients
were examined by an independent neurologist, who may
have been able to detect subtle neurologic defects after
CAS. In addition, we were unable to clearly identify the
cause of death for a significant proportion of our patients.
While many of these deaths appeared to be sudden, they
may have been neurologic in nature, which could also have
led to an undercounting of the number of strokes. Second,
our choice of CAS device and EPD varied across patients,
encompassing both open-cell and closed-cell designs. Vari-
ation across devices may have affected our results,22 al-
though significant differences in outcomes across designs
have not yet been described. Additionally, most of the
variation in device and EPD type was encountered early in
our series and would be unlikely to have skewed results
throughout. Third, myocardial infarction was not tracked
as an endpoint. While it would seem that MHR patients
would be more likely to suffer from heart attacks or other
cardiac events than NR patients, our analysis did not reveal
a difference in mortality between the two groups. Similarly,
in the comparison between CAS and CEA patients, there
was no significant difference in mortality. Therefore, even if
there was a difference in cardiac events between any of the
groups that we compared, it did not affect mortality.
Fourth, while our study has one of the longest follow-up
periods published to date, even longer follow-up could
demonstrate statistically significant differences in mortalityamong the studied groups. This effect was seen in
NASCET in patients with moderate stenosis; the benefit of
CEA was not seen at 2 years of follow-up, but was seen at 5
years.2,3 Lastly, it is important to note that the MHR
criteria were developed to predict periprocedural high risk,
not long-term survival. While it seems reasonable that
criteria such as age, renal function, and lipid levels would
also predict long-term survival, this presumption has not
yet been validated.
In summary, the presence of MHR did not impact
long-term survival or stroke rate after CAS, and overall
survival of MHR patients in our series was comparable with
controls undergoing CEA. Patients over 80 years of age
had poor survival over 3 years, and are unlikely to gain
benefit from CAS if asymptomatic. These results suggest
the need for more refined predictors of medical risk to
optimally guide patients in selecting carotid revasculariza-
tion strategies.
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